KENILWORTH, N.J., January 10, 2022 /3BLMedia/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced an additional $150 million commitment through Merck for Mothers to further advance the initiative’s mission of helping create a world where no woman has to die giving life.
Learn how our teams mobilized like never before to ensure we were ready to address a global need
Multimedia with summary
From the earliest stages of the COVID-19 pandemic, we knew we had a responsibility to mobilize and innovate to rise to the challenge of this unique moment.
We can’t do it alone. That’s why we’re saying a huge thank you.
Blog
Taking on COVID-19 isn’t just a team effort — it’s also a global one. Here at Merck, we’re grateful to all the people who have worked hard to keep us safe, along with everyone around the world helping to combat the pandemic.
The Companies Are Committed To Providing Timely Access to Molnupiravir Through Comprehensive Supply and Access Approach
Blog
KENILWORTH, N.J. & MIAMI, December 28, 2021, /3BLMedia/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for molnupiravir, an investigational oral antiviral (MK-4482, EIDD-2801).
A meal distribution program that started at the beginning of the pandemic continues to deliver thousands of meals a week to underserved communities
Blog
When the COVID-19 pandemic shuttered our offices in the spring of 2020 and thousands of employees began working remotely, our company found itself with a dilemma: lots of food in the cafeterias, but no one to eat it.
Rather than let it go to waste, Merck and FLIK Hospitality Group, our corporate dining partner, began looking for a way to put the food to use.
KENILWORTH, N.J., December 13, 2021 /3BLMedia/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its inaugural issuance of a $1 billion sustainability bond, which was part of an $8 billion underwritten public offering of notes that closed on Dec. 10, 2021.
Our company is collaborating with a range of partners to enable access for patients around the world
Multimedia with summary
At the outset of our research efforts for COVID-19, our company made clear its commitment to make any vaccine or medicine we develop for this pandemic broadly accessible.
How every division at Merck is pitching in to address a global need
Blog
The SARS-CoV-2 pandemic has touched everyone’s lives, and a task as monumental as fighting back against COVID-19 takes more than just one person — or even just one department. From the earliest stages of the pandemic, we knew we had a responsibility to mobilize our scientific expertise and experience to help address the pandemic.
Dedicated teams across our company have come together to respond to this unique challenge. Because a global crisis calls for a global response.
We are proud to support the Hiring Our Heroes Corporate Fellowship Program, bringing fantastic members to our team! Learn more about our support for veterans here: http://bit.ly/3lF5iQR
